Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder

Attention-deficit/hyperactivity disorder (ADHD) affects a large number of children. For decades, the stimulants have been the mainstay of pharmacological treatment for ADHD. Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-(R,R)-MPH, was recently introduced a...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychiatric disease and treatment 2006-12, Vol.2 (4), p.467-473
Main Authors: Liu, Feng, Minami, Haruka, Silva, Raul R
Format: Article
Language:English
Subjects:
Attention deficit hyperactivity disorder
Drug therapy
Expert Opinion
Pharmacodynamics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3727-363efcc1226b3ff66a9a8080be25a2e152e7963f839ff73e9047cdd41ba06c783
cites cdi_FETCH-LOGICAL-c3727-363efcc1226b3ff66a9a8080be25a2e152e7963f839ff73e9047cdd41ba06c783
container_end_page 473
container_issue 4
container_start_page 467
container_title Neuropsychiatric disease and treatment
container_volume 2
creator Liu, Feng
Minami, Haruka
Silva, Raul R
description Attention-deficit/hyperactivity disorder (ADHD) affects a large number of children. For decades, the stimulants have been the mainstay of pharmacological treatment for ADHD. Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-(R,R)-MPH, was recently introduced as another potential option in the stimulant class of medications. This paper reviews and summarizes the available research literature on d-MPH regarding pharmacodynamic, pharmacokinetic, chemical structure, receptor binding, toxicology, and clinical perspectives. d-MPH potentially may offer some advantages in the realms of absorption and duration of action compared with its racemic counterpart. The differences in pharmacokinetics and clinical implications of the immediate-release and extended-release forms of d-MPH are also compared and contrasted.
doi_str_mv 10.2147/nedt.2006.2.4.467
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2671958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2222763178</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3727-363efcc1226b3ff66a9a8080be25a2e152e7963f839ff73e9047cdd41ba06c783</originalsourceid><addsrcrecordid>eNpdkUtr3DAUhUVpaB7tD-imGArZ2dHLemwCJY-2EMgmWRahka5qBduaSprQ-ffxJEObVhtduOcczuVD6CPBHSVcns3ga0cxFh3teMeFfIOOCJGqpZiSt8-zaAWj6hAdl_KAMZNaqXfokGhOKNf9EfpxCb8nqMN2XA8wR28rNMPW5-SGMeXooYlzUwdoagZbJ5hrk0Jja12mmObGQ4gu1sWzhmxdjY-xbhsfS8oe8nt0EOxY4MP-P0H311d3F9_am9uv3y--3LSOSSpbJhgE5wilYsVCEMJqq7DCK6C9pUB6ClILFhTTIUgGGnPpvOdkZbFwUrETdP6Su96sJvBuKZftaNY5TjZvTbLR_LuZ42B-pkdDhSS63wWc7gNy-rWBUs0Ui4NxtDOkTTEUE616zBfh5_-ED2mT5-U4Q5cnBSPPfciLyuVUSobwpwrBZofO7NCZHTpDDTcLusXz6fUNfx17VuwJANGYfQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2222763178</pqid></control><display><type>article</type><title>Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Liu, Feng ; Minami, Haruka ; Silva, Raul R</creator><creatorcontrib>Liu, Feng ; Minami, Haruka ; Silva, Raul R</creatorcontrib><description>Attention-deficit/hyperactivity disorder (ADHD) affects a large number of children. For decades, the stimulants have been the mainstay of pharmacological treatment for ADHD. Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-(R,R)-MPH, was recently introduced as another potential option in the stimulant class of medications. This paper reviews and summarizes the available research literature on d-MPH regarding pharmacodynamic, pharmacokinetic, chemical structure, receptor binding, toxicology, and clinical perspectives. d-MPH potentially may offer some advantages in the realms of absorption and duration of action compared with its racemic counterpart. The differences in pharmacokinetics and clinical implications of the immediate-release and extended-release forms of d-MPH are also compared and contrasted.</description><identifier>ISSN: 1176-6328</identifier><identifier>EISSN: 1178-2021</identifier><identifier>DOI: 10.2147/nedt.2006.2.4.467</identifier><identifier>PMID: 19412495</identifier><language>eng</language><publisher>New Zealand: Taylor &amp; Francis Ltd</publisher><subject>Attention deficit hyperactivity disorder ; Drug therapy ; Expert Opinion ; Pharmacodynamics</subject><ispartof>Neuropsychiatric disease and treatment, 2006-12, Vol.2 (4), p.467-473</ispartof><rights>Copyright Taylor &amp; Francis Ltd. 2006</rights><rights>2006 Dove Medical Press Limited. All rights reserved 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3727-363efcc1226b3ff66a9a8080be25a2e152e7963f839ff73e9047cdd41ba06c783</citedby><cites>FETCH-LOGICAL-c3727-363efcc1226b3ff66a9a8080be25a2e152e7963f839ff73e9047cdd41ba06c783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2222763178/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2222763178?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19412495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Feng</creatorcontrib><creatorcontrib>Minami, Haruka</creatorcontrib><creatorcontrib>Silva, Raul R</creatorcontrib><title>Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder</title><title>Neuropsychiatric disease and treatment</title><addtitle>Neuropsychiatr Dis Treat</addtitle><description>Attention-deficit/hyperactivity disorder (ADHD) affects a large number of children. For decades, the stimulants have been the mainstay of pharmacological treatment for ADHD. Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-(R,R)-MPH, was recently introduced as another potential option in the stimulant class of medications. This paper reviews and summarizes the available research literature on d-MPH regarding pharmacodynamic, pharmacokinetic, chemical structure, receptor binding, toxicology, and clinical perspectives. d-MPH potentially may offer some advantages in the realms of absorption and duration of action compared with its racemic counterpart. The differences in pharmacokinetics and clinical implications of the immediate-release and extended-release forms of d-MPH are also compared and contrasted.</description><subject>Attention deficit hyperactivity disorder</subject><subject>Drug therapy</subject><subject>Expert Opinion</subject><subject>Pharmacodynamics</subject><issn>1176-6328</issn><issn>1178-2021</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkUtr3DAUhUVpaB7tD-imGArZ2dHLemwCJY-2EMgmWRahka5qBduaSprQ-ffxJEObVhtduOcczuVD6CPBHSVcns3ga0cxFh3teMeFfIOOCJGqpZiSt8-zaAWj6hAdl_KAMZNaqXfokGhOKNf9EfpxCb8nqMN2XA8wR28rNMPW5-SGMeXooYlzUwdoagZbJ5hrk0Jja12mmObGQ4gu1sWzhmxdjY-xbhsfS8oe8nt0EOxY4MP-P0H311d3F9_am9uv3y--3LSOSSpbJhgE5wilYsVCEMJqq7DCK6C9pUB6ClILFhTTIUgGGnPpvOdkZbFwUrETdP6Su96sJvBuKZftaNY5TjZvTbLR_LuZ42B-pkdDhSS63wWc7gNy-rWBUs0Ui4NxtDOkTTEUE616zBfh5_-ED2mT5-U4Q5cnBSPPfciLyuVUSobwpwrBZofO7NCZHTpDDTcLusXz6fUNfx17VuwJANGYfQ</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>Liu, Feng</creator><creator>Minami, Haruka</creator><creator>Silva, Raul R</creator><general>Taylor &amp; Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7TK</scope><scope>5PM</scope></search><sort><creationdate>20061201</creationdate><title>Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder</title><author>Liu, Feng ; Minami, Haruka ; Silva, Raul R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3727-363efcc1226b3ff66a9a8080be25a2e152e7963f839ff73e9047cdd41ba06c783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Attention deficit hyperactivity disorder</topic><topic>Drug therapy</topic><topic>Expert Opinion</topic><topic>Pharmacodynamics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Feng</creatorcontrib><creatorcontrib>Minami, Haruka</creatorcontrib><creatorcontrib>Silva, Raul R</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>ProQuest research library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Neurosciences Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropsychiatric disease and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Feng</au><au>Minami, Haruka</au><au>Silva, Raul R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder</atitle><jtitle>Neuropsychiatric disease and treatment</jtitle><addtitle>Neuropsychiatr Dis Treat</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>2</volume><issue>4</issue><spage>467</spage><epage>473</epage><pages>467-473</pages><issn>1176-6328</issn><eissn>1178-2021</eissn><abstract>Attention-deficit/hyperactivity disorder (ADHD) affects a large number of children. For decades, the stimulants have been the mainstay of pharmacological treatment for ADHD. Dexmethylphenidate (d-MPH), the d-isomer of the traditional racemic mixtures of d,l-threo-(R,R)-MPH, was recently introduced as another potential option in the stimulant class of medications. This paper reviews and summarizes the available research literature on d-MPH regarding pharmacodynamic, pharmacokinetic, chemical structure, receptor binding, toxicology, and clinical perspectives. d-MPH potentially may offer some advantages in the realms of absorption and duration of action compared with its racemic counterpart. The differences in pharmacokinetics and clinical implications of the immediate-release and extended-release forms of d-MPH are also compared and contrasted.</abstract><cop>New Zealand</cop><pub>Taylor &amp; Francis Ltd</pub><pmid>19412495</pmid><doi>10.2147/nedt.2006.2.4.467</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1176-6328
ispartof Neuropsychiatric disease and treatment, 2006-12, Vol.2 (4), p.467-473
issn 1176-6328
1178-2021
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2671958
source Publicly Available Content Database; PubMed Central
subjects Attention deficit hyperactivity disorder
Drug therapy
Expert Opinion
Pharmacodynamics
title Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A05%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dexmethylphenidate%20hydrochloride%20in%20the%20treatment%20of%20attention%20deficit%20hyperactivity%20disorder&rft.jtitle=Neuropsychiatric%20disease%20and%20treatment&rft.au=Liu,%20Feng&rft.date=2006-12-01&rft.volume=2&rft.issue=4&rft.spage=467&rft.epage=473&rft.pages=467-473&rft.issn=1176-6328&rft.eissn=1178-2021&rft_id=info:doi/10.2147/nedt.2006.2.4.467&rft_dat=%3Cproquest_pubme%3E2222763178%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3727-363efcc1226b3ff66a9a8080be25a2e152e7963f839ff73e9047cdd41ba06c783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2222763178&rft_id=info:pmid/19412495&rfr_iscdi=true